UNIVERSITY OF CALIFORNIA, DAVIS
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1905-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucdavis.edu
Clinical Trials
750
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (619 trials with phase data)• Click on a phase to view related trials
Intralesional Cyclosporine for Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Drug: CycloSPORINE Injectable ProductDrug: Saline Solution
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 12
- Registration Number
- NCT07029204
- Locations
- 🇺🇸
University of California, Davis - Dermatology Department, Sacramento, California, United States
Personalized Accelerated Intermittent Theta Burst Stimulation for Post-Acute Suicidal Ideation
- Conditions
- Major Depressive Disorder (MDD)Suicidal Ideation
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 25
- Registration Number
- NCT07025720
Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment
- Conditions
- Opioid Use Disorder
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 3492
- Registration Number
- NCT07024498
- Locations
- 🇺🇸
El Centro Regional Medical Center Emergency Department, El Centro, California, United States
🇺🇸University of California Irvine Emergency Department, Irvine, California, United States
🇺🇸Marshall Medical Center Emergency Department, Placerville, California, United States
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
- Conditions
- Metastatic Lobular Breast Carcinoma
- Interventions
- Drug: [68Ga]Ga DOTA-5G
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT07020806
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
- Conditions
- Cutaneous Squamous Cell Carcinoma of the Head and NeckClinically Node-Negative (cN0)High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
- Interventions
- Procedure: Sentinel lymph node biopsy (SLNB)Procedure: LymphadenectomyDrug: Adjuvant Definitive Therapy
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 24
- Registration Number
- NCT06990737
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 150
- Next
News
UC Davis Scientists Develop Non-Hallucinogenic LSD Derivative That Shows Promise for Schizophrenia Treatment
Researchers at UC Davis created JRT, a novel compound derived from LSD by repositioning just two atoms in its molecular structure, potentially offering a breakthrough treatment for schizophrenia without hallucinogenic effects.
Promising Alzheimer's Vaccine Targeting Tau Protein Advances Toward Human Trials
University of New Mexico researchers have developed a vaccine that generates antibodies against pathological tau protein (pT181), showing efficacy in both mice and non-human primates with strong immune responses.
CRISPR-Cas9 Reduces VEGF Levels in Monkeys, Shows Retinal Toxicity at High Doses
CRISPR-Cas9 targeting VEGFA delivered via AAV vectors reduces VEGF levels in monkeys, potentially treating choroidal neovascularisation (CNV).